MAIA Biotechnology
Chicago
About MAIA Biotechnology
MAIA Biotechnology develops cancer therapies focused on targeting telomeres via immunotherapy. It advances ateganosine (THIO / 6-thio-2’-deoxyguanosine), a small molecule that is incorporated into telomeres of telomerase-active cancer cells. Once integrated, ateganosine alters telomere structure, triggering DNA damage responses, telomere “uncapping,” and cell death, and stimulates immune response when used sequentially with checkpoint inhibitor therapies. The company also runs a second-generation discovery program to generate novel telomere-targeting agents with improved specificity and anticancer activity. It has nominated molecular entity candidates (e.g. MAIA-2021-20, MAIA-2022-12) for preclinical development.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Total funding: $75.7M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2026)
- Ticker: nysemkt:MAIA
- Website: maiabiotech.com
- Phone: 312-416-8592
Industries & Categories
Biotechnology, Health Care, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/maia-biotechnology-55551 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.